Form 4: Castle Biosciences COO Kristen Oelschlager Sells Shares Under 10b5-1 Plan

Kristen Oelschlager, COO of Castle Biosciences, sold shares of common stock on September 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Kristen Oelschlager, the Chief Operating Officer of Castle Biosciences, sold shares of the company's common stock on September 3, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 15, 2024.
• A total of 4,582 shares were sold at a weighted-average price of $28.998, with individual trades ranging from $28.58 to $29.44.
• An additional 1,250 shares were sold at a weighted-average price of $29.969, with individual trades ranging from $29.70 to $30.10.
• Following these transactions, Oelschlager directly owns 134,841 shares of Castle Biosciences common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports on insider trading activity under a pre-planned 10b5-1 plan, which is a common and legal practice. It doesn't inherently indicate positive or negative sentiment about the company's future prospects.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sales were pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under a 10b5-1 plan are generally viewed as less informative.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates